let question = {
    "data": {
      "events": {
        "event": [
          {
            "rollover": {
              "css": "this"
            },
            "rollout": {
              "css": "this"
            }
          },
          {
            "rollover": {
              "css": "this"
            },
            "rollout": {
              "css": "this"
            }
          },
          {
            "click": {
              "css": "this",
              "function": [
                "this",
                "this"
              ]
            }
          },
          {
            "click": {
              "css": "this",
              "function": "this"
            }
          },
          {
            "click": {
              "function": "this"
            }
          },
          {
            "click": {
              "function": "this"
            }
          },
          {
            "click": {
              "anim": "openingText",
              "function": "this"
            }
          },
          {
            "click": {
              "function": "this"
            }
          },
          {
            "click": {
              "function": "this"
            }
          },
          {
            "click": {
              "function": "this"
            }
          },
          {
            "click": {
              "function": "this"
            }
          },
          {
            "click": {
              "anim": "q1bg"
            }
          },
          {
            "click": {
              "anim": "passbg"
            }
          },
          {
            "click": {
              "anim": "passbg"
            }
          },
          {
            "click": {
              "anim": "failbg"
            }
          },
          {
            "click": {
              "anim": "failbg"
            }
          },
          {
            "click": {
              "css": "this",
              "function": "this"
            }
          }
        ]
      },
      "box": [
        "",
        "",
        {
          "box": [
            "",
            ""
          ]
        },
        {
          "text": {
            "__cdata": "<h1 class=\"black\">Prometric MCQ - CPR - Section - 11</h1><p class=\"p_20_black\">Welcome to MedicalMCQ4All.com</p><p class=\"p_20_black\">For each questions, Read the MCQ and select anyone option then we will show you the correct answer with descriptions.</p>"
          },
          "button": {
            "__cdata": "Let's go!"
          }
        }
      ],
      "custom": {
        "settings": "",
        "question": [
          {
            "box": [
              "",
              ""
            ],
            "text": {
              "__cdata": "<p class=\"p_20\">1. Treatment of malignant hyperthermia is?</p>"
            },
            "option": [
              {
                "text": {
                  "__cdata": "<p class=\"p_16 white\">A. Cold songing</p>"
                }
              },
              {
                "text": {
                  "__cdata": "<p class=\"p_16 white\">B. Dantrolene</p>"
                }
              },
              {
                "text": {
                  "__cdata": "<p class=\"p_16 white\">C. Atropine</p>"
                }
              },
              {
                "text": {
                  "__cdata": "<p class=\"p_16 white\">D. Amentidine</p>"
                }
              }
            ],
            "fb": [
              {
                "box": {
                  "text": {
                    "__cdata": "<p class=\"p_20 black\">Correct!</p><p>Correct answer is B : Dantrolene<br/><br><a target=\"_blank\" href=\"http://en.wikipedia.org/wiki/Malignant_hyperthermia\">http://en.wikipedia.org/wiki/Malignant_hyperthermia</a><br />\nIndications for treatment of malignant hyperthermia (MH) with dantrolene include signs of hypermetabolism, a rapid rise in carbon dioxide in the face of an increase in the minute ventilation, tachycardia, muscle and or jaw rigidity (after succinylcholine), and fever (a late sign)..</p>"
                  },
                  "button": {
                    "__cdata": "Next"
                  }
                }
              },
              {
                "box": {
                  "text": {
                    "__cdata": "<p class=\"p_20 black\">Nope!</p><p>Correct answer is B : Dantrolene<br/><br><a target=\"_blank\" href=\"http://en.wikipedia.org/wiki/Malignant_hyperthermia\">http://en.wikipedia.org/wiki/Malignant_hyperthermia</a><br />\nIndications for treatment of malignant hyperthermia (MH) with dantrolene include signs of hypermetabolism, a rapid rise in carbon dioxide in the face of an increase in the minute ventilation, tachycardia, muscle and or jaw rigidity (after succinylcholine), and fever (a late sign)..</p>"
                  },
                  "button": {
                    "__cdata": "Next"
                  }
                }
              }
            ]
          },
          {
            "box": [
              "",
              ""
            ],
            "text": {
              "__cdata": "<p class=\"p_20\">2. Torsades de pointes is seen on ECG as distinct characteristic in? (select Most appropriate one)</p>"
            },
            "option": [
              {
                "text": {
                  "__cdata": "<p class=\"p_16 white\">A. Supraventricular tachycardia</p>"
                }
              },
              {
                "text": {
                  "__cdata": "<p class=\"p_16 white\">B. Ventricular tachycardia</p>"
                }
              },
              {
                "text": {
                  "__cdata": "<p class=\"p_16 white\">C. Polymorphic ventricular tachycardia</p>"
                }
              },
              {
                "text": {
                  "__cdata": "<p class=\"p_16 white\">D. Atrial fibrillation</p>"
                }
              },
              {
                "text": {
                  "__cdata": "<p class=\"p_16 white\">E. Venricular fibrillation</p>"
                }
              }
            ],
            "fb": [
              {
                "box": {
                  "text": {
                    "__cdata": "<p class=\"p_20 black\">Correct!</p><p>Correct answer is C : Polymorphic ventricular tachycardia<br/>Torsades de pointes or torsade de pointes (TdP or simply torsade(s)) (French: [t??sadd?pw??t], translated as \"twisting of the spikes\"), describes a condition of the heart. It is a polymorphic ventricular tachycardia that exhibits distinct characteristics on the electrocardiogram (ECG). It was described by Dessertenne in 1966..</p>"
                  },
                  "button": [
                    {
                      "__cdata": "Next"
                    },
                    {
                      "__cdata": "Previous"
                    }
                  ]
                }
              },
              {
                "box": {
                  "text": {
                    "__cdata": "<p class=\"p_20 black\">Nope!</p><p>Correct answer is C : Polymorphic ventricular tachycardia<br/>Torsades de pointes or torsade de pointes (TdP or simply torsade(s)) (French: [t??sadd?pw??t], translated as \"twisting of the spikes\"), describes a condition of the heart. It is a polymorphic ventricular tachycardia that exhibits distinct characteristics on the electrocardiogram (ECG). It was described by Dessertenne in 1966..</p>"
                  },
                  "button": [
                    {
                      "__cdata": "Next"
                    },
                    {
                      "__cdata": "Previous"
                    }
                  ]
                }
              }
            ]
          },
          {
            "box": [
              "",
              ""
            ],
            "text": {
              "__cdata": "<p class=\"p_20\">3. Brain injury is likely to happen if cardiac arrest goes untreated for more than?</p>"
            },
            "option": [
              {
                "text": {
                  "__cdata": "<p class=\"p_16 white\">A. One minutes.</p>"
                }
              },
              {
                "text": {
                  "__cdata": "<p class=\"p_16 white\">B. Two minutes</p>"
                }
              },
              {
                "text": {
                  "__cdata": "<p class=\"p_16 white\">C. Three minutes</p>"
                }
              },
              {
                "text": {
                  "__cdata": "<p class=\"p_16 white\">D. Five minutes</p>"
                }
              }
            ],
            "fb": [
              {
                "box": {
                  "text": {
                    "__cdata": "<p class=\"p_20 black\">Correct!</p><p>Correct answer is D : Five minutes.</p>"
                  },
                  "button": [
                    {
                      "__cdata": "Next"
                    },
                    {
                      "__cdata": "Previous"
                    }
                  ]
                }
              },
              {
                "box": {
                  "text": {
                    "__cdata": "<p class=\"p_20 black\">Nope!</p><p>Correct answer is D : Five minutes.</p>"
                  },
                  "button": [
                    {
                      "__cdata": "Next"
                    },
                    {
                      "__cdata": "Previous"
                    }
                  ]
                }
              }
            ]
          },
          {
            "box": [
              "",
              ""
            ],
            "text": {
              "__cdata": "<p class=\"p_20\">4. Which of the following is non shockable rhythm by defibrillator?</p>"
            },
            "option": [
              {
                "text": {
                  "__cdata": "<p class=\"p_16 white\">A. Ventricular fibrillation</p>"
                }
              },
              {
                "text": {
                  "__cdata": "<p class=\"p_16 white\">B. Pulse less ventricular tachycardia</p>"
                }
              },
              {
                "text": {
                  "__cdata": "<p class=\"p_16 white\">C. Pulseless electrical activity(PEA)</p>"
                }
              },
              {
                "text": {
                  "__cdata": "<p class=\"p_16 white\">D. All are non shockable</p>"
                }
              }
            ],
            "fb": [
              {
                "box": {
                  "text": {
                    "__cdata": "<p class=\"p_20 black\">Correct!</p><p>Correct answer is C : Pulseless electrical activity(PEA)<br/>Clinicians classify cardiac arrest into \"shockable\" versus \"non–shockable\", as determined by the ECG rhythm. This refers to whether a particular class ofcardiac dysrhythmia is treatable using defibrillation.The two \"shockable\" rhythms are ventricular fibrillation and pulseless ventricular tachycardia while the two \"non–shockable\" rhythms are asystole and pulseless electrical activity..</p>"
                  },
                  "button": [
                    {
                      "__cdata": "Next"
                    },
                    {
                      "__cdata": "Previous"
                    }
                  ]
                }
              },
              {
                "box": {
                  "text": {
                    "__cdata": "<p class=\"p_20 black\">Nope!</p><p>Correct answer is C : Pulseless electrical activity(PEA)<br/>Clinicians classify cardiac arrest into \"shockable\" versus \"non–shockable\", as determined by the ECG rhythm. This refers to whether a particular class ofcardiac dysrhythmia is treatable using defibrillation.The two \"shockable\" rhythms are ventricular fibrillation and pulseless ventricular tachycardia while the two \"non–shockable\" rhythms are asystole and pulseless electrical activity..</p>"
                  },
                  "button": [
                    {
                      "__cdata": "Next"
                    },
                    {
                      "__cdata": "Previous"
                    }
                  ]
                }
              }
            ]
          },
          {
            "box": [
              "",
              ""
            ],
            "text": {
              "__cdata": "<p class=\"p_20\">5. 60-70% of cardiac arrest is due to?</p>"
            },
            "option": [
              {
                "text": {
                  "__cdata": "<p class=\"p_16 white\">A. Coronary heart disease</p>"
                }
              },
              {
                "text": {
                  "__cdata": "<p class=\"p_16 white\">B. Pulmonary embolism</p>"
                }
              },
              {
                "text": {
                  "__cdata": "<p class=\"p_16 white\">C. Electrolyte imbalance</p>"
                }
              },
              {
                "text": {
                  "__cdata": "<p class=\"p_16 white\">D. Hypothermia</p>"
                }
              },
              {
                "text": {
                  "__cdata": "<p class=\"p_16 white\">E. Hypovolumia</p>"
                }
              }
            ],
            "fb": [
              {
                "box": {
                  "text": {
                    "__cdata": "<p class=\"p_20 black\">Correct!</p><p>Correct answer is A : Coronary heart disease<br/>Approximately 60–70% of SCD is related to coronary heart disease. Among adults, ischemic heart disease is the predominant cause of arrestwith 30% of people at autopsy showing signs of recent myocardial infarction.<br />\nhttp://en.wikipedia.org/wiki/Torsades_de_pointes.</p>"
                  },
                  "button": [
                    {
                      "__cdata": "Next"
                    },
                    {
                      "__cdata": "Previous"
                    }
                  ]
                }
              },
              {
                "box": {
                  "text": {
                    "__cdata": "<p class=\"p_20 black\">Nope!</p><p>Correct answer is A : Coronary heart disease<br/>Approximately 60–70% of SCD is related to coronary heart disease. Among adults, ischemic heart disease is the predominant cause of arrestwith 30% of people at autopsy showing signs of recent myocardial infarction.<br />\nhttp://en.wikipedia.org/wiki/Torsades_de_pointes.</p>"
                  },
                  "button": [
                    {
                      "__cdata": "Next"
                    },
                    {
                      "__cdata": "Previous"
                    }
                  ]
                }
              }
            ]
          },
          {
            "box": [
              "",
              ""
            ],
            "text": {
              "__cdata": "<p class=\"p_20\">6. in suspected Cardiac arrest patient, which site pulse is recommended to feel?</p>"
            },
            "option": [
              {
                "text": {
                  "__cdata": "<p class=\"p_16 white\">A. Radial pulse</p>"
                }
              },
              {
                "text": {
                  "__cdata": "<p class=\"p_16 white\">B. Carotid pulse</p>"
                }
              },
              {
                "text": {
                  "__cdata": "<p class=\"p_16 white\">C. Femoral pulse</p>"
                }
              },
              {
                "text": {
                  "__cdata": "<p class=\"p_16 white\">D. Brachial pulse</p>"
                }
              }
            ],
            "fb": [
              {
                "box": {
                  "text": {
                    "__cdata": "<p class=\"p_20 black\">Correct!</p><p>Correct answer is B : Carotid pulse<br/>A cardiac arrest is usually diagnosed clinically by the absence of a pulse. In many cases lack of carotid pulse is the gold standard for diagnosing cardiac arrest, but lack of a pulse (particularly in the peripheral pulses) may result from other conditions (e.g. shock), or simply an error on the part of the rescuer. Studies have shown that rescuers often make a mistake when checking the carotid pulse in an emergency, whether they are healthcare professionals or lay persons..</p>"
                  },
                  "button": [
                    {
                      "__cdata": "Next"
                    },
                    {
                      "__cdata": "Previous"
                    }
                  ]
                }
              },
              {
                "box": {
                  "text": {
                    "__cdata": "<p class=\"p_20 black\">Nope!</p><p>Correct answer is B : Carotid pulse<br/>A cardiac arrest is usually diagnosed clinically by the absence of a pulse. In many cases lack of carotid pulse is the gold standard for diagnosing cardiac arrest, but lack of a pulse (particularly in the peripheral pulses) may result from other conditions (e.g. shock), or simply an error on the part of the rescuer. Studies have shown that rescuers often make a mistake when checking the carotid pulse in an emergency, whether they are healthcare professionals or lay persons..</p>"
                  },
                  "button": [
                    {
                      "__cdata": "Next"
                    },
                    {
                      "__cdata": "Previous"
                    }
                  ]
                }
              }
            ]
          },
          {
            "box": [
              "",
              ""
            ],
            "text": {
              "__cdata": "<p class=\"p_20\">7. Targeted temperature management is done in which type of patient?</p>"
            },
            "option": [
              {
                "text": {
                  "__cdata": "<p class=\"p_16 white\">A. Cardiac arrest</p>"
                }
              },
              {
                "text": {
                  "__cdata": "<p class=\"p_16 white\">B. ROSC (return of spontaneous circulation)</p>"
                }
              },
              {
                "text": {
                  "__cdata": "<p class=\"p_16 white\">C. Pulse less electrical activity</p>"
                }
              },
              {
                "text": {
                  "__cdata": "<p class=\"p_16 white\">D. ventricullar fibrillation</p>"
                }
              }
            ],
            "fb": [
              {
                "box": {
                  "text": {
                    "__cdata": "<p class=\"p_20 black\">Correct!</p><p>Correct answer is B : ROSC (return of spontaneous circulation)<br/>Targeted temperature management<br />\nCooling a person after cardiac arrest who has a return of spontaneous circulation (ROSC) but no return of consciousness improves outcomes.This procedure is called targeted temperature management (previously known as therapeutic hypothermia). People are typically cooled for a 24-hour period, with a target temperature of 32–34 °C (90–93 °F). Death rates in the hypothermia group are 35% lower than in those with no temperature management.Complicationsare generally no greater in those who receive this therapy.<br />\nA November 2013 trial found that actively cooling to a temperature of 36 °C (97 °F) results in the same outcomes as 33 °C (91 °F).This may be because preventing fever, rather than the hypothermia itself, is more important.Other possible reasons could be the long time of >8 hours needed to cool in the 33 °C group and the very high rate of bystander of CPR compared to usual international rates.<br />\nEarlier versus later cooling may result in better outcomes.[A trial that cooled in the ambulance, however, found no difference compared to starting cooling in-hospital.A registry database found poor neurological outcome increased by 8% with each five-minute delay in initiating TH and by 17% for every 30-minute delay in time to target temperature..</p>"
                  },
                  "button": [
                    {
                      "__cdata": "Next"
                    },
                    {
                      "__cdata": "Previous"
                    }
                  ]
                }
              },
              {
                "box": {
                  "text": {
                    "__cdata": "<p class=\"p_20 black\">Nope!</p><p>Correct answer is B : ROSC (return of spontaneous circulation)<br/>Targeted temperature management<br />\nCooling a person after cardiac arrest who has a return of spontaneous circulation (ROSC) but no return of consciousness improves outcomes.This procedure is called targeted temperature management (previously known as therapeutic hypothermia). People are typically cooled for a 24-hour period, with a target temperature of 32–34 °C (90–93 °F). Death rates in the hypothermia group are 35% lower than in those with no temperature management.Complicationsare generally no greater in those who receive this therapy.<br />\nA November 2013 trial found that actively cooling to a temperature of 36 °C (97 °F) results in the same outcomes as 33 °C (91 °F).This may be because preventing fever, rather than the hypothermia itself, is more important.Other possible reasons could be the long time of >8 hours needed to cool in the 33 °C group and the very high rate of bystander of CPR compared to usual international rates.<br />\nEarlier versus later cooling may result in better outcomes.[A trial that cooled in the ambulance, however, found no difference compared to starting cooling in-hospital.A registry database found poor neurological outcome increased by 8% with each five-minute delay in initiating TH and by 17% for every 30-minute delay in time to target temperature..</p>"
                  },
                  "button": [
                    {
                      "__cdata": "Next"
                    },
                    {
                      "__cdata": "Previous"
                    }
                  ]
                }
              }
            ]
          },
          {
            "box": [
              "",
              ""
            ],
            "text": {
              "__cdata": "<p class=\"p_20\">8. Epinephrine in Cardiac arrest patient used for?</p>"
            },
            "option": [
              {
                "text": {
                  "__cdata": "<p class=\"p_16 white\">A. Increase cardiac out put</p>"
                }
              },
              {
                "text": {
                  "__cdata": "<p class=\"p_16 white\">B. Increase cardiac output and vasoconstriction</p>"
                }
              },
              {
                "text": {
                  "__cdata": "<p class=\"p_16 white\">C. Vasodilatation and increase cardiac output</p>"
                }
              },
              {
                "text": {
                  "__cdata": "<p class=\"p_16 white\">D. Increase blood pressure</p>"
                }
              }
            ],
            "fb": [
              {
                "box": {
                  "text": {
                    "__cdata": "<p class=\"p_20 black\">Correct!</p><p>Correct answer is B : Increase cardiac output and vasoconstriction<br/>http://acls-algorithms.com/acls-drugs/acls-and-epinephrine/<br />\nabove is excellent link for ACLS info<br />\nEpinephrine is the primary drug used in the pulseless arrest algorithm. It is used for its potent vasoconstrictive effects and also for its ability to increase cardiac output. Epinephrine is considered a vasopressor.<br />\nIndications for ACLS<br />\nVasoconstriction effects: epinephrine binds directly to alpha-1 adrenergic receptors of the blood vessels (arteries and veins) causing direct vasoconstriction, thus, improving perfusion pressure to the brain and heart.<br />\nCardiac Output: epinephrine also binds to beta-1-adrenergic receptors of the heart. This indirectly improves cardiac output by:<br />\nIncreasing heart rate<br />\nIncreasing heart muscle contractility<br />\nIncreasing conductivity through the AV node<br />\nEpinephrine is used in the pulseless arrest algorithm as a direct IV push and also in the bradycardia algorithm as an infusion..</p>"
                  },
                  "button": [
                    {
                      "__cdata": "Next"
                    },
                    {
                      "__cdata": "Previous"
                    }
                  ]
                }
              },
              {
                "box": {
                  "text": {
                    "__cdata": "<p class=\"p_20 black\">Nope!</p><p>Correct answer is B : Increase cardiac output and vasoconstriction<br/>http://acls-algorithms.com/acls-drugs/acls-and-epinephrine/<br />\nabove is excellent link for ACLS info<br />\nEpinephrine is the primary drug used in the pulseless arrest algorithm. It is used for its potent vasoconstrictive effects and also for its ability to increase cardiac output. Epinephrine is considered a vasopressor.<br />\nIndications for ACLS<br />\nVasoconstriction effects: epinephrine binds directly to alpha-1 adrenergic receptors of the blood vessels (arteries and veins) causing direct vasoconstriction, thus, improving perfusion pressure to the brain and heart.<br />\nCardiac Output: epinephrine also binds to beta-1-adrenergic receptors of the heart. This indirectly improves cardiac output by:<br />\nIncreasing heart rate<br />\nIncreasing heart muscle contractility<br />\nIncreasing conductivity through the AV node<br />\nEpinephrine is used in the pulseless arrest algorithm as a direct IV push and also in the bradycardia algorithm as an infusion..</p>"
                  },
                  "button": [
                    {
                      "__cdata": "Next"
                    },
                    {
                      "__cdata": "Previous"
                    }
                  ]
                }
              }
            ]
          },
          {
            "box": [
              "",
              ""
            ],
            "text": {
              "__cdata": "<p class=\"p_20\">9. During ACLS, epinephrine can be given by all except?</p>"
            },
            "option": [
              {
                "text": {
                  "__cdata": "<p class=\"p_16 white\">A. Intravenous</p>"
                }
              },
              {
                "text": {
                  "__cdata": "<p class=\"p_16 white\">B. Intraosseous</p>"
                }
              },
              {
                "text": {
                  "__cdata": "<p class=\"p_16 white\">C. Endotracheal</p>"
                }
              },
              {
                "text": {
                  "__cdata": "<p class=\"p_16 white\">D. Subcutaneous</p>"
                }
              }
            ],
            "fb": [
              {
                "box": {
                  "text": {
                    "__cdata": "<p class=\"p_20 black\">Correct!</p><p>Correct answer is D : Subcutaneous<br/>For use in cardiopulmonary resuscitation (CPR), specifically, for the treatment of cardiac arrest (pulseless electrical activity or ventricular asystole), or as an adjunct to electrical defibrillation in the treatment of ventricular fibrillation/pulseless ventricular tachycardia.<br />\nIntermittent Intravenous or Intraosseus† dosage<br />\nAdults<br />\n1 mg (10 mL of a 0.1 mg/mL solution) IV or IO; may repeat every 3 to 5 minutes. Do not interrupt CPR to administer drug therapy. Higher doses of epinephrine are not recommended except when indicated for exceptional circumstances (e.g., beta-blocker overdosage).<br />\n<br><a target=\"_blank\" href=\"https://www.pdr.net/drug-summary/Adrenalin-epinephrine-3036\">https://www.pdr.net/drug-summary/Adrenalin-epinephrine-3036</a>.</p>"
                  },
                  "button": [
                    {
                      "__cdata": "Next"
                    },
                    {
                      "__cdata": "Previous"
                    }
                  ]
                }
              },
              {
                "box": {
                  "text": {
                    "__cdata": "<p class=\"p_20 black\">Nope!</p><p>Correct answer is D : Subcutaneous<br/>For use in cardiopulmonary resuscitation (CPR), specifically, for the treatment of cardiac arrest (pulseless electrical activity or ventricular asystole), or as an adjunct to electrical defibrillation in the treatment of ventricular fibrillation/pulseless ventricular tachycardia.<br />\nIntermittent Intravenous or Intraosseus† dosage<br />\nAdults<br />\n1 mg (10 mL of a 0.1 mg/mL solution) IV or IO; may repeat every 3 to 5 minutes. Do not interrupt CPR to administer drug therapy. Higher doses of epinephrine are not recommended except when indicated for exceptional circumstances (e.g., beta-blocker overdosage).<br />\n<br><a target=\"_blank\" href=\"https://www.pdr.net/drug-summary/Adrenalin-epinephrine-3036\">https://www.pdr.net/drug-summary/Adrenalin-epinephrine-3036</a>.</p>"
                  },
                  "button": [
                    {
                      "__cdata": "Next"
                    },
                    {
                      "__cdata": "Previous"
                    }
                  ]
                }
              }
            ]
          },
          {
            "box": [
              "",
              ""
            ],
            "text": {
              "__cdata": "<p class=\"p_20\">10. how much IV epinephrine is given during ACLS per guideline?</p>"
            },
            "option": [
              {
                "text": {
                  "__cdata": "<p class=\"p_16 white\">A. 1mg every 2 minutes</p>"
                }
              },
              {
                "text": {
                  "__cdata": "<p class=\"p_16 white\">B. 1 mg every 3-5 minutes</p>"
                }
              },
              {
                "text": {
                  "__cdata": "<p class=\"p_16 white\">C. 2mg every 3-5 minutes</p>"
                }
              },
              {
                "text": {
                  "__cdata": "<p class=\"p_16 white\">D. 2 mg every 2 minutes</p>"
                }
              }
            ],
            "fb": [
              {
                "box": {
                  "text": {
                    "__cdata": "<p class=\"p_20 black\">Correct!</p><p>Correct answer is B : 1 mg every 3-5 minutes<br/>For use in cardiopulmonary resuscitation (CPR), specifically, for the treatment of cardiac arrest (pulseless electrical activity or ventricular asystole), or as an adjunct to electrical defibrillation in the treatment of ventricular fibrillation/pulseless ventricular tachycardia.<br />\nIntermittent Intravenous or Intraosseus† dosage<br />\nAdults<br />\n1 mg (10 mL of a 0.1 mg/mL solution) IV or IO; may repeat every 3 to 5 minutes. Do not interrupt CPR to administer drug therapy. Higher doses of epinephrine are not recommended except when indicated for exceptional circumstances (e.g., beta-blocker overdosage)..</p>"
                  },
                  "button": {
                    "__cdata": "Previous"
                  }
                }
              },
              {
                "box": {
                  "text": {
                    "__cdata": "<p class=\"p_20 black\">Nope!</p><p>Correct answer is B : 1 mg every 3-5 minutes<br/>For use in cardiopulmonary resuscitation (CPR), specifically, for the treatment of cardiac arrest (pulseless electrical activity or ventricular asystole), or as an adjunct to electrical defibrillation in the treatment of ventricular fibrillation/pulseless ventricular tachycardia.<br />\nIntermittent Intravenous or Intraosseus† dosage<br />\nAdults<br />\n1 mg (10 mL of a 0.1 mg/mL solution) IV or IO; may repeat every 3 to 5 minutes. Do not interrupt CPR to administer drug therapy. Higher doses of epinephrine are not recommended except when indicated for exceptional circumstances (e.g., beta-blocker overdosage)..</p>"
                  },
                  "button": {
                    "__cdata": "Previous"
                  }
                }
              }
            ]
          }
        ],
        "timeout": {
          "box": {
            "box": {
              "text": {
                "__cdata": "<p class=\"p_42 grey\">Times up!</p>"
              },
              "button": {
                "__cdata": "Start again"
              }
            }
          }
        },
        "score": {
          "fb": [
            {
              "box": {
                "box": {
                  "text": {
                    "__cdata": "<p class=\"p_30 white glow\">CONGRATULATIONS!</p><p class=\"p_20 orange glow\">You scored [score]%</p>"
                  },
                  "button": {
                    "__cdata": "Play again?"
                  }
                }
              }
            },
            {
              "box": {
                "box": {
                  "text": {
                    "__cdata": "<p class=\"p_32 white glow\">Bad luck! You scored [score]%</p><p class=\"p_20 orange glow\">Why not have another go?</p>"
                  },
                  "button": {
                    "__cdata": "Start again"
                  }
                }
              }
            }
          ]
        }
      }
    }
  }